U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07442006) titled 'Glycemic Variability of Combination Therapies in T2DM' on Jan. 21.
Brief Summary: Glycemic Variability of Combination Therapies in T2DM
Study Start Date: Oct. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
DRUG: Empagliflozin/Metformin
5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUG: Anagliptin
100 mg, for 12 weeks (PO, BID)
DRUG: Metformin
500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUG: Empagliflozin/Linagliptin
10/5 mg, for 12 weeks (PO, QD)
Recruitment Status: RECRUITING
Sponsor: JW Pharmaceutical
Published...